Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Celgene Corporation (NASDAQ:CELG) today announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to the previously...
WeissLaw LLP Investigates Juno Therapeutics Inc. Acquisition PR Newswire NEW YORK, Jan. 24, 2018 NEW YORK, Jan. 24, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Juno Therapeutics, Inc. PR Newswire NEW YORK, Jan. 22, 2018 NEW YORK, Jan. 22, 2018 /PRNewswire/ -- Rowley Law PLLC is...
Johnson Fistel, Announces Investigations of the Proposed Sales of Bioverativ Inc., and Juno Therapeutics, Inc. PR Newswire SAN DIEGO, Jan. 22, 2018 SAN DIEGO, Jan. 22, 2018 /PRNewswire/...
Acquisition Will Add Novel Scientific Platform and Manufacturing Expertise to Celgene’s Research and Operational Capabilities JCAR017 is Expected to be a Significant Growth Driver...
Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the appointment of Cindy...
Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced that it will webcast its presentation at the 36th Annual J.P. Morgan Healthcare Conference at 4:00 p.m. PT on Tuesday, January 9, 2018...
Juno Therapeutics and Thermo Fisher Scientific Announce CAR T Manufacturing Partnership PR Newswire WALTHAM, Mass., Dec. 20, 2017 WALTHAM, Mass., Dec. 20, 2017 /PRNewswire/ -- Juno Therapeutics...
—Updated JCAR017 (liso-cel) data in core group at dose level 2 showed 74% (14/19) ORR and 68% (13/19) CR rate at 3 months, with 50% (7/14) CR at 6 months— —JCAR017 data continue to...
—74% (14/19) ORR and 68% (13/19) CR rate at 3 months and 50% (7/14) CR at 6 months in core group at dose level 2— —Across doses, 80% (16/20) of core group patients in CR at month 3...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
